Ewing sarcoma · 11 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
TC, then IE, VDoxoC, VEC N/A - secondary systemic drug | — | R 90 531 | 21d | — | — | — | — | — |
VAdCA/IE N/A - protocol | — | R 31 328 | 21d | — | — | — | — | — |
VAI Variant #02 | — | R 26 252 | 21d | — | — | — | — | — |
VIDE Variant #01 | — | R 19 393 | 21d | — | — | — | — | — |
VAdCA N/A - protocol | — | R 12 544 | 21d | — | — | — | — | — |
ICE Variant #01 | — | R 11 539 | 14d | — | ~13.9 mo | — | — | — |
Cyclophosphamide and Topotecan Variant #01 | — | R 6 079 | 21d | — | — | — | — | — |
IE N/A - secondary systemic drug | — | R 5 678 | 28d | — | — | — | — | — |
Busulfan and Melphalan Variant #01 | — | R 5 233 | — | — | — | — | — | 1 |
Docetaxel and Gemcitabine Variant #01 | — | R 4 912 | 21d | ~6.2 mo | — | ~9 | ~R 44 207 PFS proxy · indirect | 1 |
Irinotecan and Temozolomide Variant #01 | — | R 2 971 | 28d | — | — | — | — | — |
11 of 11 regimens shown